HPV Testing & PAP Test Market is anticipated to grow at a CAGR of 6.8% during the forecast period 2023-2032

The global HPV testing & PAP test market was valued at USD 3.7 billion in 2022 and it is anticipated to grow further till USD 7.2 billion by 2032, at a CAGR of 6.8% during the forecast period.

To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS24644

The most prevalent sexually transmitted infection in the world is caused by the papillomaviridae family's Human Papillomavirus (HPV). A double-stranded DNA tumor virus called the human papillomavirus promotes the growth of epithelial cells on the cutaneous and mucosal surfaces. HPV is divided into two categories, such as low-risk HPVs and high-risk HPVs, depending on the risk involved. About 14 HPV varieties, including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68, are considered high-risk. Cervical and vaginal cancers are now well known to be caused by high-risk strains of the HPV virus. The most oncogenic HPV type, HPV 16, causes over half of all cervical cancers, and HPV 16 and 18 together cause around 70% of cervical cancers.

Read more about HPV Testing & PAP Test Market here: https://www.globalinsightservices.com/reports/hpv-testing-pap-test-market

Market Driver and Trends:

The rise in cervical cancer incidences worldwide, the expansion of cervical cancer screening programmes, and the adoption of cutting-edge technology are the market's main growth drivers. The World Health Organization (WHO) estimates that more than 500,000 women will get cervical cancer in 2020, and 342,000 will pass away as a result. In accordance with the World Health Assembly's endorsement of WHO's global strategy for eradicating cervical cancer in 2020, 70% of women worldwide must undergo routine high-performance cervical cancer screenings, and 90% of those who do so must receive the necessary treatment, which may include surgery.

Global HPV Testing & PAP Test Market Segmentation

By Test Type
• HPV Test
• Pap Test
• Co-test

By Application
• Cervical Cancer
• Vaginal Cancer

By Location of Testing
• Hospitals & Clinics
• Diagnostic Centers
• Others

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS24644

COVID-19 Impact:

On the market, the COVID-19 epidemic had a considerable effect. Healthcare services, especially the identification of numerous ailments, decreased as a result of the lockdown and suspension of trade in many nations. With the COVID-19 pandemic spreading across the globe in 2020, it was discovered that many elective medical procedures, including cancer screening, were mostly postponed in order to prioritise other essential requirements and lower the chance of COVID-19 spreading. This has revealed a marked decrease in cancer screening. The primary concerns of national healthcare organisations and global healthcare systems, however, have been cancer care and upholding high standards for diagnosis and treatment.

Major Players in the Global HPV Testing & PAP Test Market:

The report analyses various key players such as Arbor Vita Corporation, Danaher Corporation (Cepheid), Seegene Inc., Becton, Dickinson and Company, TruScreen, Abbott Laboratories, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and OncoHealth Corporation among others.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS24644/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.